NanoViricides Inc (NNVC) - Total Liabilities
Based on the latest financial reports, NanoViricides Inc (NNVC) has total liabilities worth $1.18 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is NanoViricides Inc growing its equity to track the company's year-over-year net asset growth rate.
NanoViricides Inc - Total Liabilities Trend (2005–2025)
This chart illustrates how NanoViricides Inc's total liabilities have evolved over time, based on quarterly financial data.
NanoViricides Inc Competitors by Total Liabilities
The table below lists competitors of NanoViricides Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Brooks Laboratories Limited
NSE:BROOKS
|
India | Rs242.82 Million |
|
Sportshero Ltd
AU:SHO
|
Australia | AU$1.11 Million |
|
NWP Holdings Bhd
KLSE:5025
|
Malaysia | RM21.82 Million |
|
QMINES LTD
F:81V
|
Germany | €3.41 Million |
|
Caravelle International Group
NASDAQ:HTCO
|
USA | $19.76 Million |
|
Zodiac Clothing Company Limited
NSE:ZODIACLOTH
|
India | Rs1.63 Billion |
|
Agat Ejendomme A/S
CO:AGAT
|
Denmark | Dkr502.00 Million |
|
BRAINCOOL AB
F:5YL
|
Germany | €16.58 Million |
Liability Composition Analysis (2005–2025)
This chart breaks down NanoViricides Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see NanoViricides Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NanoViricides Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NanoViricides Inc (2005–2025)
The table below shows the annual total liabilities of NanoViricides Inc from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $1.31 Million | -3.85% |
| 2024-06-30 | $1.36 Million | -33.21% |
| 2023-06-30 | $2.03 Million | +392.75% |
| 2022-06-30 | $412.84K | +17.57% |
| 2021-06-30 | $351.15K | -83.72% |
| 2020-06-30 | $2.16 Million | -24.29% |
| 2019-06-30 | $2.85 Million | +222.94% |
| 2018-06-30 | $881.95K | -86.80% |
| 2017-06-30 | $6.68 Million | -50.82% |
| 2016-06-30 | $13.59 Million | +9.55% |
| 2015-06-30 | $12.40 Million | -22.32% |
| 2014-06-30 | $15.96 Million | +90.10% |
| 2013-06-30 | $8.40 Million | +371.89% |
| 2012-06-30 | $1.78 Million | +203.08% |
| 2011-06-30 | $587.18K | -76.26% |
| 2010-06-30 | $2.47 Million | +379.65% |
| 2009-06-30 | $515.72K | -49.66% |
| 2008-06-30 | $1.02 Million | +20.55% |
| 2007-06-30 | $849.88K | -43.00% |
| 2006-06-30 | $1.49 Million | +2159.13% |
| 2005-06-30 | $66.00K | -- |
About NanoViricides Inc
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product for… Read more